Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2009 Results and Announces Share Repurchase
Date:8/17/2009

, based on the nature of the work that the employee was assigned to perform, totaled RMB5.6 million (US$0.8 million) for the second quarter of 2009. Share-based compensation expenses for the second quarter of 2008 were RMB6.4 million. For the first six months of 2009, share-based compensation expenses totaled RMB11.9 million (US$1.7 million), which represented a decrease of 11.4% from RMB13.4 million for the same period in 2008.

Income from operations was RMB37.9 million (US$5.5 million) for the second quarter of 2009, which represented a decrease of 61.4% from RMB98.1 million for the same period in 2008. For the first six months of 2009, operating income was RMB98.9 million (US$14.5 million), which represented a decrease of 49.9% from RMB197.3 million for the same period in 2008.

Income tax benefit for the second quarter of 2009 was RMB3.4 million (US$0.5 million), compared to an income tax expense of RMB18.1 million for the same period in 2008. The decrease in income tax expense for the second quarter of 2009 was primarily due to lower taxable income, the reduced income tax rates for certain operating subsidiaries effective from 2009 and the recognition of deferred tax benefits by certain operating subsidiaries as a result of the tax losses incurred in the second quarter of 2009. For the first six months of 2009, income tax expense was RMB4.2 million (US$0.6 million) compared to RMB34.9 million for the same period in 2008.

Net income attributable to Simcere was RMB37.2 million (US$5.5 million) for the second quarter of 2009, compared to RMB95.2 million for the same period in 2008. Net income margin was 8.8% for the second quarter of 2009, compared to 21.8% for the second quarter of 2008. For the first six months of 2009, net income was RMB85.4 million (US$12.5 million), which represented a decrease of 58.8% from RMB207.3 million for the same period in 2008. Net margin for the first six months of 200
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
11. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a ... one of its portfolio companies, Acclarent, Inc., has ... by Ethicon, Inc., a Johnson & Johnson company, ... (net of estimated cash on hand at time ... designing, developing and commercializing devices that address conditions ...
(Date:12/16/2009)... never felt so good for "The Biggest Loser" Danny ... continuing to make smart choices everyday to help him ... choice that is an important part of living well. ... glass of milk has nine essential nutrients like protein ... pressure, and calcium and vitamin D for strong bones. ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... role in reducing inflammation in the lungs , , WEDNESDAY, ... plays a role in inflammation seems to protect the ... who smoke. , Researchers also found that adult smokers ... lower risk of developing chronic obstructive pulmonary disease (COPD), ... "The gene seems to be protective of the lungs ...
(Date:12/16/2009)... omega-3 essential fatty acids commonly found in fatty ... according to research published by the American Psychological ... information-processing problems found in people with schizophrenia; bipolar, ... other afflictions of the nervous system. , ... Neuroscience , provides more evidence that fish is ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:New study links DHA type of omega-3 to better nervous-system function 2
... association exists between depression severity and poor Glycaemic control ... of the diabetics were found having received mental health ... Columbia University's Mailman School of Public Health and College ... 200 Hispanics with diabetes. "We found a steady increase ...
... genetics, more importance is being given to the tendency of ... the same. // A recent study has now shown that ... on dialysis. ,What is even more alarming is ... that can be treated at early stages. Family members of ...
... survival rate of patients with testicular cancer has increased significantly ... now shown that fatherhood is a reachable possibility for many ... the most common form of cancer among men ages 20 ... side than on the left. The cause for the cancer ...
... Research has leaned in a big way towards eating up ... studies presented at the meeting extolled on the virtues of ... experts are now of the view that the best way ... you eat, in other words diet modification may actually add ...
... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
... an important signaling pathway in prostate cancer cells, thereby ... of Vitamin E // that limits the proliferation of ... study are the first to describe the role of ... TAP in prostate cancer. Expression levels of TAP are ...
Other Medicine News:Health News:Testicular Cancer Patients Have Improved Reproductive Outcomes After Treatment 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
(Date:12/16/2009)... -- Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ) ... version of a common single-letter variant in the ... impact on susceptibility to type 2,diabetes (T2D). The ... large, but unusual:,if an individual inherits it from ... more than 30% compared to those who inherit ...
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 213 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 113 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 2Red Cross Strives to Help Disasters Vulnerable Population 59839 1Red Cross Strives to Help Disasters Vulnerable Population 59839 2Red Cross Strives to Help Disasters Vulnerable Population 59839 3Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 1Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 2
... presented at ICAAC -, BRIDGEWATER, N.J., Sept. ... open-label Phase 3 study showed that 84 percent ... of,PREZISTA(TM) (darunavir) 800 mg (two 400 mg tablets) ... and tenofovir disoproxil,fumarate) reached an undetectable viral load ...
... 18 - A,multi-disciplinary group of researchers from the ... Maryland Biotechnology Institute (UMBI),has won a competitive, $2 ... way researchers develop and test pharmaceutical drugs., ... Distinguished,Professor and chair of the Fischell Department of ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
All Day Comfort for the Lower Body...
All Purpose, General Procedure Apron...
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: